Grants & Programs

Elucidating the Biology for Clinical Success of Cancer Vaccines and Future Outlook for Cancer Immunotherapy

Date:
March 18, 2010
Time:
07:00 AM
Location:
Washington, DC

March 18-20, 2010
Washington, DC

The Cancer Immunotherapy Consortium hosted its 11th Scientific Colloquium, “Elucidating the Biology for Clinical Success of Cancer Vaccines,” and the 9th Annual Meeting, “Future Outlook for Cancer Immunotherapy,” in Washington, DC. The meeting included 25 plenary presentations from world-leading immunologists and tumor immunologists from both academia and industry who shared and discussed data from the latest laboratory investigations, as well as both early- and late-phase clinical trials of cancer immunotherapies.


Keynote Address

  • Mario Eisenberger, Johns Hopkins University School of Medicine

  • F. Stephen Hodi, Dana-Farber Cancer Institute


Recent Results from Immunotherapy Programs

  • Philip Bergman, BrightHeart Veterinary Clinic

  • Mark Frohlich, Dendreon Corporation

  • Jon Richards, Lutheran General Hospital Cancer Center

  • Jeffrey Schlom, National Cancer Institute, NIH

  • Kerry Wentworth, Antigenics, LLC


Kinetics of Cancer Vaccine Biology

  • Tito Fojo, National Cancer Institute, NIH

  • Wolf Fridman, Unité INSERM 255

  • Axel Hoos, Bristol-Myers Squibb

  • Robert Schreiber, Washington University

  • Cassian Yee, Fred Hutchinson Cancer Research Center

  • Allan Zajac, University of Alabama at Birmingham


Opportunities for Surrogrates

  • Peter Choyke, National Cancer Institute

  • John Eberhardt, DecisionQ

  • Steve Larson, Memorial Sloan-Kettering Cancer Center

  • Douglas McNeel, University of Wisconsin School of Medicine and Public Health

  • Howard Scher, Memorial Sloan-Kettering Cancer Center


Status and Outlook for the Cancer Vaccine Consortium

  • Martin Birkhofer, Bristol-Myers Squibb Company

  • Chantal Cazeault, Health Canada

  • Axel Hoos, Bristol-Myers Squibb Company

  • Hyam Levitsky, Johns Hopkins University


Public Consultation Workshop on Minimal Information About T-Cell Assays (Miata)

  • Cedrik Britten, Johannes Gutenberg – University Mainz

  • Sylvia Janetzki, ZellNetConsulting


Immune Monitoring Session

  • Cedrik Britten, Johannes Gutenberg - University Mainz

  • Sylvia Janetzki, ZellNet Consulting, Inc

  • Lisa McNeil, Pfizer Vaccine Research      

  • Kunle Odunsi, Roswell Park Cancer Institute

- See more at: http://cri-stage.ecentricarts.com/cic/colloquium/2010#sthash.ygDuIVdn.dpuf

March 18-20, 2010
Washington, DC

The Cancer Immunotherapy Consortium hosted its 11th Scientific Colloquium, “Elucidating the Biology for Clinical Success of Cancer Vaccines,” and the 9th Annual Meeting, “Future Outlook for Cancer Immunotherapy,” in Washington, DC. The meeting included 25 plenary presentations from world-leading immunologists and tumor immunologists from both academia and industry who shared and discussed data from the latest laboratory investigations, as well as both early- and late-phase clinical trials of cancer immunotherapies.


Keynote Address

  • Mario Eisenberger, Johns Hopkins University School of Medicine

  • F. Stephen Hodi, Dana-Farber Cancer Institute


Recent Results from Immunotherapy Programs

  • Philip Bergman, BrightHeart Veterinary Clinic

  • Mark Frohlich, Dendreon Corporation

  • Jon Richards, Lutheran General Hospital Cancer Center

  • Jeffrey Schlom, National Cancer Institute, NIH

  • Kerry Wentworth, Antigenics, LLC


Kinetics of Cancer Vaccine Biology

  • Tito Fojo, National Cancer Institute, NIH

  • Wolf Fridman, Unité INSERM 255

  • Axel Hoos, Bristol-Myers Squibb

  • Robert Schreiber, Washington University

  • Cassian Yee, Fred Hutchinson Cancer Research Center

  • Allan Zajac, University of Alabama at Birmingham


Opportunities for Surrogrates

  • Peter Choyke, National Cancer Institute

  • John Eberhardt, DecisionQ

  • Steve Larson, Memorial Sloan-Kettering Cancer Center

  • Douglas McNeel, University of Wisconsin School of Medicine and Public Health

  • Howard Scher, Memorial Sloan-Kettering Cancer Center


Status and Outlook for the Cancer Vaccine Consortium

  • Martin Birkhofer, Bristol-Myers Squibb Company

  • Chantal Cazeault, Health Canada

  • Axel Hoos, Bristol-Myers Squibb Company

  • Hyam Levitsky, Johns Hopkins University


Public Consultation Workshop on Minimal Information About T-Cell Assays (Miata)

  • Cedrik Britten, Johannes Gutenberg – University Mainz

  • Sylvia Janetzki, ZellNetConsulting


Immune Monitoring Session

  • Cedrik Britten, Johannes Gutenberg - University Mainz

  • Sylvia Janetzki, ZellNet Consulting, Inc

  • Lisa McNeil, Pfizer Vaccine Research      

  • Kunle Odunsi, Roswell Park Cancer Institute

- See more at: http://cri-stage.ecentricarts.com/cic/colloquium/2010#sthash.ygDuIVdn.dpuf

The Cancer Immunotherapy Consortium hosted its 11th Scientific Colloquium, “Elucidating the Biology for Clinical Success of Cancer Vaccines,” and the 9th Annual Meeting, “Future Outlook for Cancer Immunotherapy,” March 18-20, 2010, in Washington, DC. The meeting included 25 plenary presentations from world-leading immunologists and tumor immunologists from both academia and industry who shared and discussed data from the latest laboratory investigations, as well as both early- and late-phase clinical trials of cancer immunotherapies.


Keynote Address

  • Mario Eisenberger, Johns Hopkins University School of Medicine

  • F. Stephen Hodi, Dana-Farber Cancer Institute


Recent Results from Immunotherapy Programs 

  • Philip Bergman, BrightHeart Veterinary Clinic

  • Mark Frohlich, Dendreon Corporation

  • Jon Richards, Lutheran General Hospital Cancer Center

  • Jeffrey Schlom, National Cancer Institute, NIH

  • Kerry Wentworth, Antigenics, LLC


Kinetics of Cancer Vaccine Biology

  • Tito Fojo, National Cancer Institute, NIH

  • Wolf Fridman, Unité INSERM 255

  • Axel Hoos, Bristol-Myers Squibb

  • Robert Schreiber, Washington University

  • Cassian Yee, Fred Hutchinson Cancer Research Center

  • Allan Zajac, University of Alabama at Birmingham


Opportunities for Surrogrates

  • Peter Choyke, National Cancer Institute

  • John Eberhardt, DecisionQ

  • Steve Larson, Memorial Sloan-Kettering Cancer Center

  • Douglas McNeel, University of Wisconsin School of Medicine and Public Health

  • Howard Scher, Memorial Sloan-Kettering Cancer Center


Status and Outlook for the Cancer Vaccine Consortium

  • Martin Birkhofer, Bristol-Myers Squibb Company

  • Chantal Cazeault, Health Canada

  • Axel Hoos, Bristol-Myers Squibb Company

  • Hyam Levitsky, Johns Hopkins University


Public Consultation Workshop on Minimal Information About T-Cell Assays (MIATA)

  • Cedrik Britten, Johannes Gutenberg – University Mainz

  • Sylvia Janetzki, ZellNetConsulting


Immune Monitoring Session

  • Cedrik Britten, Johannes Gutenberg - University Mainz

  • Sylvia Janetzki, ZellNet Consulting, Inc

  • Lisa McNeil, Pfizer Vaccine Research      

  • Kunle Odunsi, Roswell Park Cancer Institute


Contact Us

Want to learn more about the Cancer Immunotherapy Consortium? Contact a CIC representative at consortium@cancerresearch.org or (212) 688-7515.